US stock · figures in US dollars · scored on full-year results
Elevance Health Elevance Health, Inc. Common Stock
Elevance Health scores 41/100 on fundamentals: in the bottom 16% of 503 scored S&P 500 stocks. Its strongest area is Financial Safety (75/100); its weakest is Price Fairness (17/100). It carries 1 warning flag: Weak Spot.
- Carries a Weak Spot flag
This stock is fairly balanced overall: price fairness is its weakest area.
Nearby peers
Ranks #49 of 60 in Healthcare by score
One-Minute Summary
Why Elevance Health scores 41
This stock is fairly balanced overall: price fairness is its weakest area.
Business Strength
20Why 20?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 17.8% over 4 years: customers keep spending more with this company.
Profit fell about 14.2% from where it was 4 years ago: the boom has cooled off.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 11.9% over the last 8 quarters: customers keep spending more with this company.
Profit grew about 44% over the last 8 quarters: the business is keeping more of what it earns.
Financial Safety
75Why 75?
No data: Current Ratio
Show chart
Debt vs Equity, with D/E ratio
Borrowings grew about 22.4% over 4 years: watch this; rising debt adds pressure in bad times.
Cash & Dividends
63Why 63?
Show 3 charts
Operating vs Free Cash Flow
Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
17Why 17?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 35.1% over the past year.
Risk
40Why 40?
No data: Inventory vs Sales (4yr)
Sector peers
Elevance Health (ELV) scores 41/100 (Okay) on Score Your Stock's educational fundamentals model: in the bottom 16% of 503 scored S&P 500 stocks.
Its strongest pillar is Financial Safety (75/100); its weakest is Price Fairness (17/100).
Elevance Health ranks #49 of 60 scored Healthcare stocks on Score Your Stock.
Yes. Elevance Health (ELV) has a dividend yield of 1.6%, from dividends with an ex-date in the last 12 months. It pays out 29% of its profit as dividends. Its Cash & Dividends pillar scores 63/100.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy ELV. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Elevance Health (ELV) is a Healthcare company (Healthcare Plans). On Score Your Stock's fundamentals check, it scores 41/100, rated Okay. Its biggest strength is Financial Safety (75/100); its main watch-out is Price Fairness (17/100). Shares currently cost about 18 years of its current profit to buy (P/E 17.7×). It also pays back about 1.6% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/elv-elevance-health
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Total Assets | Total Liabilities | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio | PEG Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 201.8b | US$ 5.1b | US$ 7.6b | US$ 6.5b | US$ -1.1b | US$ 10.3b | US$ 30.8b | US$ 375.0m | US$ 44.7b | US$ 127.8b | US$ 83.0b | - | 12% | 3% | 0.7× | 5.3× | 29% | - | - | - | - |
| 2025 | US$ 199.1b | US$ 5.7b | US$ 4.3b | US$ 3.2b | US$ -1.1b | US$ 9.5b | US$ 32.0b | US$ 1.2b | US$ 43.9b | US$ 121.5b | US$ 77.5b | US$ 684.0m | 13% | 3% | 0.7× | 5.8× | 27% | 2% | 13.6× | 1.8× | - |
| 2024 | US$ 176.8b | US$ 6.0b | US$ 5.8b | US$ 4.6b | US$ -1.3b | US$ 8.3b | US$ 31.2b | US$ 2.0b | US$ 41.3b | US$ 116.9b | US$ 75.5b | US$ 652.0m | 14% | 3% | 0.8× | 7.7× | 25% | 2% | 13.7× | 2.0× | - |
| 2023 | US$ 171.3b | US$ 6.0b | US$ 8.1b | US$ 6.8b | US$ -1.3b | US$ 6.5b | US$ 25.1b | US$ 1.9b | US$ 39.3b | US$ 108.9b | US$ 69.5b | US$ 592.0m | 15% | 3% | 0.6× | 8.5× | 23% | 1% | 17.5× | 2.7× | 1.9 |